Search results for "From ACP Journal Club"
Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulfonylureas increases hypoglycemia
Adding dipeptidyl peptidase-4 (DPP-4) inhibitors to sulfonylureas was associated with 1 excess case of hypoglycemia for every 17 patients in the first 6 months of treatment, the systematic review and meta-analysis found.
https://diabetes.acponline.org/archives/2016/09/16/5.htm
16 Sep 2016
In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis
Taking canagliflozin, at a dose of either 100 mg or 300 mg per day, was associated with risk of diabetic ketoacidosis, according to a trial that randomized patients with type 1 diabetes to either of the doses or a placebo.
https://diabetes.acponline.org/archives/2016/08/12/5.htm
12 Aug 2016
Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations
Incretin-based drugs did not appear to be associated with greater heart failure hospitalization risk compared with commonly used combinations of oral antidiabetic drugs, a cohort study found.
https://diabetes.acponline.org/archives/2016/08/12/6.htm
12 Aug 2016
Review: In diabetes, benefits of lowering BP depend on baseline BP being 140 mm Hg or more
Hypertension treatment reduced mortality and myocardial infarction in diabetic patients with a systolic blood pressure of at least 140 mm Hg, a systematic review and meta-analysis found. However, in patients with lower baseline blood pressure (BP), treatment didn't affect overall mortality and was associated with increased cardiovascular mortality.
https://diabetes.acponline.org/archives/2016/07/15/6.htm
15 Jul 2016
In abstinent adults with type 2 diabetes, a daily glass of wine (vs mineral water) improved cardiometabolic factors
Drinking red wine, rather than mineral water, with dinner every night for 2 years was associated with improvements in cholesterol markers in patients in Israel. A group assigned to white wine did not show significant differences on these markers from the water group.
https://diabetes.acponline.org/archives/2016/03/11/6.htm
11 Mar 2016
In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years
An industry-funded trial found that those who took empagliflozin had lower rates of mortality, including from cardiovascular (CV) events, than those on placebo. A commentary in ACP Journal Club called the trial results fascinating but said they are not yet sufficient to change practice.
https://diabetes.acponline.org/archives/2016/02/12/5.htm
12 Feb 2016
In high-risk pregnant women, an individualized lifestyle intervention reduced gestational diabetes mellitus
The intervention in the Finnish study targeted women with previous gestational diabetes mellitus or a body mass index of 30 kg/m2 or greater.
https://diabetes.acponline.org/archives/2016/01/08/5.htm
8 Jan 2016
Review: In patients with type 2 diabetes who fast, sitagliptin reduces hypoglycemia more than sulfonylurea
Patients who took sitagliptin were significantly less likely to have hypoglycemia during Ramadan, according to a systematic review.
https://diabetes.acponline.org/archives/2015/11/13/6.htm
13 Nov 2015
Review: Type 2 diabetes screening does not reduce mortality but treating dysglycemia delays onset of diabetes
A systematic evidence review by the U.S. Preventive Services Task Force found no evidence of mortality benefit from screening for diabetes, based on 2 large randomized controlled trials conducted in the United Kingdom.
https://diabetes.acponline.org/archives/2015/10/09/6.htm
9 Oct 2015
Review: Intensive blood pressure control reduces retinopathy in diabetes
Intensive control of blood pressure reduced incidence of retinopathy, but not progression of established retinopathy, in patients with type 1 or 2 diabetes, according to an analysis of 15 randomized controlled trials.
https://diabetes.acponline.org/archives/2015/07/10/5.htm
10 Jul 2015